{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T18:25:20Z","timestamp":1776363920960,"version":"3.51.2"},"reference-count":35,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2026,3,30]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>Understanding uveal melanoma incidence and survival trends is crucial for improving patient outcomes and allocating healthcare resources. We aimed to investigate the incidence and survival for uveal melanoma in Norway, 1993\u20132021, including information on tumour site, tumour (T) category and summary stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Cancer Registry of Norway provided data on all patients diagnosed with a first primary uveal melanoma in Norway between 1 January 1993 and 31 December 2021. We calculated age-standardised incidence rates using the European standard population and estimated net survival and crude probability of death. Net survival estimates were obtained using the Pohar-Perme estimator, period approach and cohort approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Altogether, 1497 patients (49.6% men) were diagnosed with a primary uveal melanoma in 1993\u20132021. The age-standardised incidence rate increased from 6.8 (95% CI 5.7 to 7.9) per million person-years in 1993\u20131997\u2009to 9.8 (95% CI 8.8 to 11.0) per million person-years in 2017\u20132021, with an overall rate of 9.0 (95% CI 8.6 to 9.5). This increase was primarily driven by localised, T1 and T2 choroidal melanomas. Ten-year net survival for patients with uveal melanoma remained relatively stable between 57.2% (95% CI 36.2% to 73.5%) in 1993\u20131997\u2009and 65.5% (95% CI 53.8% to 74.9%) in 2017\u20132021. Over the same periods, there was a notable net survival improvement in patients with choroidal melanoma from 53.4% (95% CI 27.9% to 73.4%)\u2009to 74.8% (95% CI 59.8% to 84.9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The increased uveal melanoma incidence in Norway was mainly due to localised choroidal tumours. Improved detection of choroidal tumours is likely to have contributed to both the increased incidence and long-term net survival, highlighting the potential benefits of early detection strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2025-327605","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:20:27Z","timestamp":1776360027000},"page":"bjo-2025-327605","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in incidence and survival for uveal melanoma in Norway, 1993\u20132021"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7363-7856","authenticated-orcid":false,"given":"Nils","family":"Leitzinger","sequence":"first","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragnhild S","family":"Falk","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Jespersen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils A","family":"Eide","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele C","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia"},{"name":"Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trude E","family":"Robsahm","sequence":"additional","affiliation":[{"name":"Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marit B","family":"Veier\u00f8d","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"2026041610201695000_bjo-2025-327605v1.1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026041610201695000_bjo-2025-327605v1.2","doi-asserted-by":"crossref","first-page":"926034","DOI":"10.3389\/fmed.2022.926034","article-title":"Trends in Uveal Melanoma Presentation and Survival During Five Decades: A Nationwide Survey of 3898 Swedish Patients","volume":"9","author":"Gill","year":"2022","journal-title":"Front Med"},{"key":"2026041610201695000_bjo-2025-327605v1.3","doi-asserted-by":"publisher","DOI":"10.1159\/000492391"},{"key":"2026041610201695000_bjo-2025-327605v1.4","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-022-00082-y","article-title":"Long-term relative survival in uveal melanoma: a systematic review and meta-analysis","volume":"2","author":"St\u00e5lhammar","year":"2022","journal-title":"Commun Med (Lond)"},{"key":"2026041610201695000_bjo-2025-327605v1.5","unstructured":"Edge SB , editors . American Joint Committee on Cancer. 7th edn. New York: Springer, 2010:648."},{"key":"2026041610201695000_bjo-2025-327605v1.6","unstructured":"AJCC cancer staging manual. In: AJCC Cancer Staging Manual. Springer International Publishing, 2017. Available: https:\/\/link.springer.com\/deleted"},{"key":"2026041610201695000_bjo-2025-327605v1.7","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317949"},{"key":"2026041610201695000_bjo-2025-327605v1.8","unstructured":"Cancer Registry of Norway . Cancer in Norway 2021 - Cancer Incidence, Mortality, Survival and Prevalence in Norway. Oslo: Cancer Registry of Norway, 2022."},{"key":"2026041610201695000_bjo-2025-327605v1.9","unstructured":"Beahrs OH , Beahrs OH , American Joint Committee on Cancer . Manual for Staging of Cancer. 4th edn. Philadelphia: Lippincott, 1992:280."},{"key":"2026041610201695000_bjo-2025-327605v1.10","unstructured":"American Joint Committee on Cancer . AJCC Cancer Staging Manual. 5th edn. Philadelphia: Lippincott-Raven, 1997:294."},{"key":"2026041610201695000_bjo-2025-327605v1.11","doi-asserted-by":"crossref","unstructured":"Greene FL , American Joint Committee on Cancer, American Cancer Society . AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 6th edn. New York: Springer, 2002:469.","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"2026041610201695000_bjo-2025-327605v1.12","unstructured":"Ruhl JL , Callaghan C , Hurlbut A . Summary Stage 2018: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute, 2018."},{"key":"2026041610201695000_bjo-2025-327605v1.13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27651"},{"key":"2026041610201695000_bjo-2025-327605v1.14","unstructured":"European Commission. Eurostat . Revision of the european standard population: report of eurostat\u2019s task force: 2013 edition. LU: Publications Office; 2013. Available: https:\/\/data.europa.eu\/doi\/10.2785\/11470"},{"key":"2026041610201695000_bjo-2025-327605v1.15","doi-asserted-by":"publisher","DOI":"10.1177\/0962280206070621"},{"key":"2026041610201695000_bjo-2025-327605v1.16","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z"},{"key":"2026041610201695000_bjo-2025-327605v1.17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2016.11.019","article-title":"Estimation of net survival for cancer patients: Relative survival setting more robust to some assumption violations than cause-specific setting, a sensitivity analysis on empirical data","volume":"72","author":"Schaffar","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026041610201695000_bjo-2025-327605v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601295"},{"key":"2026041610201695000_bjo-2025-327605v1.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2011.01640.x"},{"key":"2026041610201695000_bjo-2025-327605v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.07.002"},{"key":"2026041610201695000_bjo-2025-327605v1.21","doi-asserted-by":"crossref","first-page":"101745","DOI":"10.1016\/j.canep.2020.101745","article-title":"Estimation of age-standardized net survival, even when age-specific data are sparse","volume":"67","author":"Rutherford","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"2026041610201695000_bjo-2025-327605v1.22","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0258(20000715)19:13<1729::AID-SIM484>3.0.CO;2-9"},{"key":"2026041610201695000_bjo-2025-327605v1.23","doi-asserted-by":"crossref","first-page":"e1474","DOI":"10.1111\/aos.14847","article-title":"Posterior uveal melanoma incidence and survival by AJCC tumour size in a 70-year nationwide cohort","volume":"99","author":"Smidt-Nielsen","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"2026041610201695000_bjo-2025-327605v1.24","doi-asserted-by":"crossref","first-page":"1001799","DOI":"10.3389\/fmed.2022.1001799","article-title":"Uveal melanoma incidence trends in Canada: 1992\u20132010 vs. 2011\u20132017","volume":"9","author":"Conte","year":"2023","journal-title":"Front Med"},{"key":"2026041610201695000_bjo-2025-327605v1.25","doi-asserted-by":"publisher","DOI":"10.1159\/000480640"},{"key":"2026041610201695000_bjo-2025-327605v1.26","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319700"},{"key":"2026041610201695000_bjo-2025-327605v1.27","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/02713683.2017.1297997","article-title":"Uveal Melanoma Risk Factors: A Systematic Review of Meta-Analyses","volume":"42","author":"Nayman","year":"2017","journal-title":"Curr Eye Res"},{"key":"2026041610201695000_bjo-2025-327605v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.01.040"},{"key":"2026041610201695000_bjo-2025-327605v1.29","doi-asserted-by":"crossref","unstructured":"Kristianslund O , Kure ISH , Drolsum L . Cataract surgery in Norway 2010\u201319. Tidsskr Nor Laegeforen 2021;141. doi:10.4045\/tidsskr.20.1005","DOI":"10.4045\/tidsskr.20.1005"},{"key":"2026041610201695000_bjo-2025-327605v1.30","doi-asserted-by":"crossref","unstructured":"Stene LC , Ruiz PLD , \u00c5svold BO , et al . Hvor mange har diabetes i norge i 2020? Tidsskr Nor Laegeforen 2020;140. doi:10.4045\/tidsskr.20.0849","DOI":"10.4045\/tidsskr.20.0849"},{"key":"2026041610201695000_bjo-2025-327605v1.31","unstructured":"L\u00f8vaas K , Madsen T , Ueland G , et al . Tilbakemeldingsrapport 2022. Norsk diabetesregister for voksne; 2022."},{"key":"2026041610201695000_bjo-2025-327605v1.32","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/aos.16598","article-title":"Intravitreal anti\u2010vascular endothelial growth factor therapy for retinal diseases in Norway from 2011 to 2021: A combined registry and survey study","volume":"102","author":"Husum","year":"2024","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"2026041610201695000_bjo-2025-327605v1.33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jamaophthalmol.2014.77","article-title":"Age, Survival Predictors, and Metastatic Death in Patients With Choroidal Melanoma: Tentative Evidence of a Therapeutic Effect on Survival","volume":"132","author":"Damato","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2026041610201695000_bjo-2025-327605v1.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.3.826"},{"key":"2026041610201695000_bjo-2025-327605v1.35","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.12.1684"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2025-327605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:20:36Z","timestamp":1776360036000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2025-327605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":35,"alternative-id":["10.1136\/bjo-2025-327605"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2025-327605","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}